These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 3072274)

  • 21. Neurochemical anatomy of movement disorders.
    Young AB; Penney JB
    Neurol Clin; 1984 Aug; 2(3):417-33. PubMed ID: 6152481
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Abnormalities of catecholamine metabolism in Parkinson's disease (author's transl)].
    Nagatsu T
    Tanpakushitsu Kakusan Koso; 1981 Aug; 26(11):1781-8. PubMed ID: 6117927
    [No Abstract]   [Full Text] [Related]  

  • 23. Dopamine denervation does not alter in vivo 3H-spiperone binding in rat striatum: implications for external imaging of dopamine receptors in Parkinson's disease.
    Bennett JP; Wooten GF
    Ann Neurol; 1986 Apr; 19(4):378-83. PubMed ID: 3707090
    [TBL] [Abstract][Full Text] [Related]  

  • 24. GABA-dopamine relationship in Parkinson's disease striatum.
    Kish S; Rajput A; Gilbert J; Rozdilsky B; Chang LJ; Shannak K; Hornykiewicz O
    Adv Neurol; 1987; 45():75-7. PubMed ID: 3825737
    [No Abstract]   [Full Text] [Related]  

  • 25. Glutamate measurement in Parkinson's disease using MRS at 3 T field strength.
    Kickler N; Krack P; Fraix V; Lebas JF; Lamalle L; Durif F; Krainik A; Rémy C; Segebarth C; Pollak P
    NMR Biomed; 2007 Dec; 20(8):757-62. PubMed ID: 17334978
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Time-dependent alterations of peripheral immune parameters after nigrostriatal dopamine depletion in a rat model of Parkinson's disease.
    Engler H; Doenlen R; Riether C; Engler A; Niemi MB; Besedovsky HO; del Rey A; Pacheco-López G; Feldon J; Schedlowski M
    Brain Behav Immun; 2009 May; 23(4):518-26. PubMed ID: 19486644
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The ability of grafted human sympathetic neurons to synthesize and store dopamine: a potential mechanism for the clinical effect of sympathetic neuron autografts in patients with Parkinson's disease.
    Nakao N; Shintani-Mizushima A; Kakishita K; Itakura T
    Exp Neurol; 2004 Jul; 188(1):65-73. PubMed ID: 15191803
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gender differences in neurotoxicity of the nigrostriatal dopaminergic system: implications for Parkinson's disease.
    Dluzen DE; McDermott JL
    J Gend Specif Med; 2000; 3(6):36-42. PubMed ID: 11253381
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term glial cell line-derived neurotrophic factor overexpression in the intact nigrostriatal system in rats leads to a decrease of dopamine and increase of tetrahydrobiopterin production.
    Sajadi A; Bauer M; Thöny B; Aebischer P
    J Neurochem; 2005 Jun; 93(6):1482-6. PubMed ID: 15935064
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Striatal molecular mechanisms and motor dysfunction in Parkinson's disease.
    Chase TN; Konitsiotis S; Oh JD
    Adv Neurol; 2001; 86():355-60. PubMed ID: 11553996
    [No Abstract]   [Full Text] [Related]  

  • 31. Damage to dopamine systems differs between Parkinson's disease and Alzheimer's disease with parkinsonism.
    Murray AM; Weihmueller FB; Marshall JF; Hurtig HI; Gottleib GL; Joyce JN
    Ann Neurol; 1995 Mar; 37(3):300-12. PubMed ID: 7695230
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impaired behavioural and molecular adaptations to dopamine denervation and repeated L-DOPA treatment in Nur77-knockout mice.
    St-Hilaire M; Bourhis E; Lévesque D; Rouillard C
    Eur J Neurosci; 2006 Aug; 24(3):795-805. PubMed ID: 16930409
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impaired acquisition of skilled behavior in rotarod task by moderate depletion of striatal dopamine in a pre-symptomatic stage model of Parkinson's disease.
    Ogura T; Ogata M; Akita H; Jitsuki S; Akiba L; Noda K; Hoka S; Saji M
    Neurosci Res; 2005 Mar; 51(3):299-308. PubMed ID: 15710494
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Parkinson's disease 20 years later].
    Guillard A
    Presse Med; 1987 Oct; 16(32):1565-6. PubMed ID: 2958829
    [No Abstract]   [Full Text] [Related]  

  • 35. The placebo effect in Parkinson's disease.
    de la Fuente-Fernández R; Stoessl AJ
    Trends Neurosci; 2002 Jun; 25(6):302-6. PubMed ID: 12086748
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The nature of Parkinson's disease.
    Calne DB
    Neurochem Int; 1992 Mar; 20 Suppl():1S-3S. PubMed ID: 1365403
    [No Abstract]   [Full Text] [Related]  

  • 37. Parkinson's disease and striatal dopamine: in vivo morphological evidence for the presence of dopamine in the human brain.
    Constantinidis J; Siegfried J; Frigyesi TL; Tissot R
    J Neural Transm; 1974; 35(1):13-22. PubMed ID: 4824675
    [No Abstract]   [Full Text] [Related]  

  • 38. Mechanisms of Parkinson's disease.
    Br Med J; 1978 Apr; 1(6117):872-3. PubMed ID: 25109
    [No Abstract]   [Full Text] [Related]  

  • 39. Impaired olfactory function in Parkinson's disease.
    Lehrner J; Brücke T; Kryspin-Exner I; Asenbaum S; Podreka I
    Lancet; 1995 Apr; 345(8956):1054-5. PubMed ID: 7723526
    [No Abstract]   [Full Text] [Related]  

  • 40. The biochemical bases for reward. Implications for the placebo effect.
    De La Fuente-Fernández R; Stoessl AJ
    Eval Health Prof; 2002 Dec; 25(4):387-98. PubMed ID: 12449082
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.